TWO · 7427.TWO
Great Novel Therapeutics Biotech & Medicals
NT$64.00+NT$0.90 (+1.43%)
Great Novel Therapeutics Biotech & Medicals’s quoted price sits in the upper half of its reported 52-week range, 22.71% below the high.
Loading market information…
TWO · 4171.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
GeneReach Biotechnology Corp.’s quoted price sits in the lower half of its reported 52-week range, 36.99% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
GeneReach Biotechnology Corp.’s forward annual dividend is NT$1.50 per share, paid annual. The forward yield is 9.17% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow GeneReach Biotechnology Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
GeneReach Biotechnology Corp., a company based in Taichung, Taiwan, specializes in the development, production, and commercialization of advanced nucleic acid detection technologies. The company's extensive product line features essential laboratory instrumentation, including automated nucleic acid extraction systems, prep homogenization systems, and mini centrifuges. GeneReach also provides a wide range of reagents and consumables, such as human In Vitro Diagnostic (IVD) assays, specific iiPCR reagents, taco nucleic acid extraction reagents, IQ real quantitative systems, IQ2000 detection and prevention systems, and various research-grade reagents and supplies. Beyond its product offerings, GeneReach delivers comprehensive services. These encompass polymerase chain reaction (PCR) training programs, expert molecular diagnostic technical solutions, laboratory installation assistance, OEM/ODM contract manufacturing capabilities, and collaborative research services. Its innovative solutions cater to a diverse clientele, with applications spanning aquaculture, agriculture, food safety, human health, and the welfare of companion animals and livestock. GeneReach Biotechnology Corp. was established in 2004.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$64.00+NT$0.90 (+1.43%)
Great Novel Therapeutics Biotech & Medicals’s quoted price sits in the upper half of its reported 52-week range, 22.71% below the high.
NT$18.70-NT$0.15 (-0.8%)
NaviFUS Corp.’s quoted price sits in the lower half of its reported 52-week range, 30.87% below the high.
NT$31.45-NT$0.05 (-0.16%)
NeoCore Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.91% below the high.
NT$22.55-NT$0.35 (-1.53%)
Bio Preventive Medicine Corp.’s quoted price sits in the lower half of its reported 52-week range, 50.98% below the high.
NT$23.00NT$0.00 (0.0%)
LabTurbo Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 11.88% below the high.
NT$13.80-NT$0.20 (-1.43%)
MegaPro Biomedical Co., Ltd’s quoted price sits in the upper half of its reported 52-week range, 19.06% below the high.
NT$23.20-NT$0.50 (-2.11%)
Excelsior Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.06% below the high.
NT$14.90-NT$0.40 (-2.61%)
Enimmune corporation’s quoted price sits in the lower half of its reported 52-week range, 33.92% below the high.
